Head-To-Head Contrast: Sonic Healthcare (OTCMKTS:SKHHY) versus Aclarion (NASDAQ:ACON)

Aclarion (NASDAQ:ACON) and Sonic Healthcare (OTCMKTS:SKHHY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.

Insider & Institutional Ownership

7.5% of Aclarion shares are held by institutional investors. Comparatively, 0.0% of Sonic Healthcare shares are held by institutional investors. 0.0% of Aclarion shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Aclarion and Sonic Healthcare”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80,000.00	79.33	-$7.23 million	($9.03)	-0.29
Sonic Healthcare	$6.25 billion	1.20	$332.61 million	N/A	N/A

Sonic Healthcare has higher revenue and earnings than Aclarion.

Analyst Recommendations

This is a summary of current ratings and price targets for Aclarion and Sonic Healthcare, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1	0	1	0	2.00
Sonic Healthcare	1	1	0	0	1.50

Aclarion currently has a consensus price target of $7.50, indicating a potential upside of 190.70%. Given Aclarion’s stronger consensus rating and higher possible upside, analysts clearly believe Aclarion is more favorable than Sonic Healthcare.

Profitability

This table compares Aclarion and Sonic Healthcare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-54.41%	-51.71%
Sonic Healthcare	N/A	N/A	N/A

Volatility & Risk

Aclarion has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Sonic Healthcare has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.

Summary

Aclarion beats Sonic Healthcare on 7 of the 12 factors compared between the two stocks.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

About Sonic Healthcare

Sonic Healthcare Limited offers medical diagnostic services to medical practitioners, hospitals, community health services, and their collective patients. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. It offers primary care medical services comprising general practice clinics, occupational health services, skin cancer clinics, after-hours general practice services, general practice IT solutions, and community-based healthcare services. The company operates in Australia, the United Kingdom, Ireland, the United States, Germany, Switzerland, New Zealand, Belgium, and internationally. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.